Skip to main content

Hypoxia Induces Resistance to 5-Fluorouracil in Oral Cancer Cells Via G1 Phase Cell Cycle Arrest

  • Conference paper
New Trends in the Molecular and Biological Basis for Clinical Oncology

Abstract

Malignant tumors are exposed to various levels of hypoxic condition in vivo. To clarify the mechanism of the hypoxia-induced chemoresistance, we evaluated the effects of hypoxia on the resistance of oral squamous cell carcinoma (OSCC) cell lines to 5-fluorouracil (5-FU). OSCC cells were divided to two groups by the proliferation activity under hypoxic condition; hypoxia-resistant (HR) and hypoxia-sensitive (HS) cells. Growth of HS cells were inhibited by hypoxia and introduced to G1 arrest in cell cycle. 5-FU effect on HS cell viability was markedly reduced in hypoxic condition without an induction of chemoresistant related protein, P-glycoprotein. However, proliferation, cell cycle, and 5-FU sensitivity of HR cells were not affected by hypoxia. Hypoxia-inducible factor (HIF)-1α was induced by hypoxia in all OSCC cell lines, but diminished in HS cells within 48 hours. Expression of p21 and p27 was strongly augmented and CyclinD expression was reduced by hypoxia in HS cells. However, expression of these proteins was constitutive in HR cells during 48h hypoxic culture. Phosphorylation of mammalian target of rapamycin (mTOR) was reduced by hypoxia in HS cells. From these findings, we concluded that HS OSCC cells acquire 5-FU resistance under hypoxia by Gl/S transition through an upregulation of cell cycle inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437–447

    Article  PubMed  CAS  Google Scholar 

  • Brown JM (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6: 157–162

    Article  PubMed  CAS  Google Scholar 

  • Janssen HL, Haustermans KM, Balm AJ, Begg AC (2005) Hypoxia in head and neck cancer: how much, how important? Head Neck 27: 622–638

    Article  PubMed  CAS  Google Scholar 

  • Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM (1991) Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 64: 809–814

    PubMed  CAS  Google Scholar 

  • Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, Yu J (2006) Hypoxiai-nduced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1 alpha gene. Cancer Chemother Pharmacol 58: 776–784

    Article  PubMed  CAS  Google Scholar 

  • Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev 13: 139–168

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer

About this paper

Cite this paper

Yoshiba, S., Ito, D., Nagumo, T., Shirota, T., Hatori, M., Shintani, S. (2009). Hypoxia Induces Resistance to 5-Fluorouracil in Oral Cancer Cells Via G1 Phase Cell Cycle Arrest. In: Tachikawa, T., Nose, K., Ohmori, T., Adachi, M. (eds) New Trends in the Molecular and Biological Basis for Clinical Oncology. Springer, Tokyo. https://doi.org/10.1007/978-4-431-88663-1_19

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-88663-1_19

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-88662-4

  • Online ISBN: 978-4-431-88663-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics